CLAIMS:

1. An adenovirus comprising a sequence of formula **(I)**:

$$5'ITR\text{-}B_1\text{-}B_A\text{-}B_2\text{-}B_X\text{-}B_B\text{-}B_Y\text{-}B_3\text{-}3'ITR \quad \textbf{(I)}$$

wherein:

B_1 is a bond or comprises: E1A, E1B or E1A-E1B;

B_A comprises-E2B-L1-L2-L3-E2A-L4;

B_2 is a bond or comprises: E3;

B_X is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both;

B_B comprises L5;

B_Y comprises a transgene cassette containing four transgenes, said genes encoding a FAP-BITE, CXCL10, CXCL9, and IFN;

B_3 is a bond or comprises: E4.

2. An adenovirus according to claim 1, wherein the encoded FAB-BITE comprises an anti-CD3 shown in SEQ ID NO: 5 or a sequence at least 95% identical thereto, such as SEQ ID NO: 5.

3. An adenovirus according to claim 1 or 2 wherein the FAP-BITE comprises an anti-FAP shown in SEQ ID NO: 9 or a sequence at least 95% identical thereto, such as SEQ ID NO: 9.

4. An adenovirus according to claim 1, wherein the encoded FAB-BITE comprises a sequence selected from SEQ ID NO: 75, 76 or a sequence at least 95% identical to any one thereof.

5. An adenovirus according to any one of claims 1 to 4, wherein the transgene cassette encodes CXCL10 shown in SEQ ID NO: 100 or a sequence at least 95% identical thereto, such as SEQ ID NO: 100.

6. An adenovirus according to any one of claims 1 to 5, wherein the transgene cassette encodes CXCL9 shown in SEQ ID NO: 99 or a sequence at least 95% identical thereto, such as SEQ ID NO: 99.

7. An adenovirus according to any one of claims 1 to 6, wherein the transgene cassette encodes IFNα shown in SEQ ID NO: 98 or a sequence at least 95% identical thereto, such as SEQ ID NO: 98.

8. An adenovirus according to any one of claims 1 to 7, wherein the transgenes are operably linked.

9. An adenovirus according to any one of claims 1 to 8, wherein the transgenes are separated by 3 different high efficiency self-cleavage peptides.

10. An adenovirus according to claim 9, wherein the self-cleavage peptides are independently selected from E2A, F2A, P2A and T2A.

11. An adenovirus according to any one of claims 1 to 10, wherein the relative order of the transgenes from L5 to E4 is FAP-BITE, CXCL10, CXCL9 and IFNα, for example as shown in Figure 1.

12. An adenovirus according to any one of claims 1 to 11, wherein the transgene cassette has a polynucleotide sequence shown in SEQ ID NO: 95 or a polynucleotide encoding the same amino acid sequence, in particular SEQ ID NO: 95.

13. An adenovirus according to any one of claims 1 to 12, wherein the adenovirus comprises SEQ ID NO: 84.

14. An adenovirus according to any one of claims 1 to 13, wherein the adenovirus is replication competent.

15. An adenovirus according to any one of claims 1 to14, wherein the adenovirus is oncolytic.

16. An adenovirus according to any one of claims 1 to 15, wherein the virus has a hexon and fibre from Ad11.

17. A pharmaceutical composition comprising an adenovirus according to any one of claims 1 to 16 and an excipient, diluent or carrier.

18. An adenovirus according to any one of claims 1 to 16, or a pharmaceutical composition according to claim 17, for use in treatment, for example for use in the treatment of cancer.

19. Use of an adenovirus according to any one of claims 1 to 16, or a pharmaceutical composition according to claim 17, for the manufacture of a medicament for the treatment of cancer.